Johnson & Johnson is a multinational corporation engaged in the development, manufacturing, and marketing of a wide range of healthcare products. The company operates through three primary segments: pharmaceuticals, medical devices, and consumer health products. Johnson & Johnson is known for its commitment to innovation in healthcare, producing a diverse array of products that include prescription medications for various diseases, sophisticated medical devices for surgical procedures, and widely recognized consumer brands for personal care and wellness. With a focus on improving health outcomes, the company aims to address the evolving needs of patients and consumers around the world. Read More
Johnson & Johnson (NYSE: JNJ) will present at the Bernstein’s 41st Annual Strategic Decisions Conference on Wednesday, May 28th, 2025. Management will participate in a Fireside Chat at 10:00 a.m. Eastern Time.
A lawsuit claims Eli Lilly, Johnson & Johnson, and Kaiser Permanente failed to warn consumers about breast cancer risks linked to their antipsychotic drugs Risperdal and Zyprexa.
Multinational healthcare company Johnson & Johnson (NYSE:JNJ) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 2.4% year on year to $21.89 billion. The company’s full-year revenue guidance of $92 billion at the midpoint came in 1.8% above analysts’ estimates. Its non-GAAP profit of $2.77 per share was 7.3% above analysts’ consensus estimates.
Johnson & Johnson has been treading water for the past six months, recording a small loss of 3.8% while holding steady at $157.30. However, the stock is beating the S&P 500’s 11% decline during that period.
Stock market expert Jon Erlichman recently shared a review of stock returns during the last six U.S. recessions, highlighting those that have performed well in difficult times.
Healthcare sector sees volatility due to UnitedHealth's earnings disappointment, but ETFs like XLV, IHE, and XPH still show resilience and pockets of strength.
